The History and Development of HER2 Inhibitors.

Xia, Xiaohui; Gong, Chen; Zhang, Yinan; Xiong, Huihua

Xia, Xiaohui; Gong, Chen; Zhang, Yinan; Xiong, Huihua.

Afiliación

Xia X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Gong C; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhang Y; School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China.
Xiong H; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Pharmaceuticals (Basel) ; 16(10)2023 Oct 12.

Article en En | MEDLINE | ID: mdl-37895921

RESUMEN

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.

Palabras clave

HER2 inhibitors; antibodies; antibody-drug conjugates; cancer; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google